HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Krajisnik, T. Articles by Larsson, T. E Search for Related Content PubMed PubMed Citation Articles by Krajisnik, T. Articles by Larsson, T. E

¹ Departments of Medical Sciences and
² Surgical Sciences, Uppsala University Hospital, 751 85 Uppsala, Sweden

(Correspondence should be addressed to T E Larsson; Email: tobias.larsson{at}medsci.uu.se)

Fibroblast growth factor-23 (FGF23) is a circulating factor that decreases serum levels of inorganic phosphate (Pi) as well as 1,25-dihydroxyvitamin D₃. Recent studies also suggest a correlation between serum levels of FGF23 and parathyroid hormone (PTH) in patients with chronic kidney disease. It is, however, unknown whether FGF23 directly modulates PTH expression, or whether the correlation is secondary to abnormalities in Pi and vitamin D metabolism. The objective of the current study was therefore to elucidate possible direct effects of FGF23 on bovine parathyroid cells in vitro. Treatment of parathyroid cells with a stabilized form of recombinant FGF23 (FGF23(R176Q)) induced a rise in early response gene-1 mRNA transcripts, a marker of FGF23 signaling. FGF23(R176Q) potently and dose-dependently decreased the PTH mRNA level within 12 h. In agreement, FGF23(R176Q) also decreased PTH secretion into conditioned media. In contrast, FGF23(R176Q) dose-dependently increased 1-hydroxylase expression within 3 h. FGF23 (R176Q) did not affect cell viability nor induce apoptosis, whereas a small but significant increase in cell proliferation was found. We conclude that FGF23 is a negative regulator of PTH mRNA expression and secretion in vitro. Our data suggest that FGF23 may be a physiologically relevant regulator of PTH. This defines a novel function of FGF23 in addition to the previously established roles in controlling vitamin D and Pi metabolism.

This article has been cited by other articles:

				W. W. Brown, H. Juppner, C. B. Langman, H. Price, E. G. Farrow, K. E. White, and K. L. McCormick Hypophosphatemia with Elevations in Serum Fibroblast Growth Factor 23 in a Child with Jansen's Metaphyseal Chondrodysplasia J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 17 - 20. [Abstract] [Full Text] [PDF]

				X. Bai, Q. Dinghong, D. Miao, D. Goltzman, and A. C. Karaplis Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype Am J Physiol Endocrinol Metab, January 1, 2009; 296(1): E79 - E88. [Abstract] [Full Text] [PDF]

				A. Gal-Moscovici and S. M. Sprague Role of Bone Biopsy in Stages 3 to 4 Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(Supplement_3): S170 - S174. [Abstract] [Full Text] [PDF]

				P. Bjorklund, T. Krajisnik, G. Akerstrom, G. Westin, and T. E. Larsson Type I Membrane Klotho Expression Is Decreased and Inversely Correlated to Serum Calcium in Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 4152 - 4157. [Abstract] [Full Text] [PDF]

				J. Danziger The bone-renal axis in early chronic kidney disease: an emerging paradigm Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2733 - 2737. [Full Text] [PDF]

				C. A. Brownstein, F. Adler, C. Nelson-Williams, J. Iijima, P. Li, A. Imura, Y.-i. Nabeshima, M. Reyes-Mugica, T. O. Carpenter, and R. P. Lifton A translocation causing increased {alpha}-Klotho level results in hypophosphatemic rickets and hyperparathyroidism PNAS, March 4, 2008; 105(9): 3455 - 3460. [Abstract] [Full Text] [PDF]

				G. van Boekel, J. Ruinemans-Koerts, F. Joosten, P. Dijkhuizen, A. van Sorge, and H. de Boer Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling Eur. J. Endocrinol., March 1, 2008; 158(3): 431 - 437. [Abstract] [Full Text] [PDF]

				G. J. Strewler Phosphate Metabolism. Meeting Report from the 29th Annual Meeting of the American Society for Bone and Mineral Research: September 16-19, 2007 in Honolulu, Hawaii, USA IBMS BoneKEy, December 1, 2007; 4(12): 342 - 345. [Full Text] [PDF]